St. Jude Neuromodulation draws warning letter
This article was originally published in The Gray Sheet
Executive Summary
FDA warning letter dated July 1 cites non-conformities with current good manufacturing practices at St. Jude's Neuromodulation division facilities in Plano, Tex., and Hackettstown, N.J., which were observed during FDA inspections in March and April. St. Jude says it has already begun addressing the issues, which pertain to manufacturing process and documentation issues, and not specific device deficiencies, according to the company. FDA says it will not approve any St. Jude Neuromodulation PMA application until the warning letter is resolved. But St. Jude notes that it does not have any major neuromodulation device filings pending. The company recently completed enrollment of a pivotal study of its Libra and LibraXP deep brain stimulation systems for symptomatic Parkinson's disease. The company says it expects to file a PMA for the indication in about 18 months
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.